0 CHECKOUT

House Dust Mite Allergy - Pipeline Review, H2 2015

  • ID: 3422663
  • August 2015
  • 55 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • ALK-Abello A/S
  • Anergis SA
  • Biomay AG
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Stallergenes S.A.
  • MORE

House Dust Mite Allergy - Pipeline Review, H2 2015

Summary

The report ‘House Dust Mite Allergy - Pipeline Review, H2 2015’, provides an overview of the House Dust Mite Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ALK-Abello A/S
  • Anergis SA
  • Biomay AG
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Stallergenes S.A.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

House Dust Mite Allergy Overview

Therapeutics Development

Pipeline Products for House Dust Mite Allergy - Overview

Pipeline Products for House Dust Mite Allergy - Comparative Analysis

House Dust Mite Allergy - Therapeutics under Development by Companies

House Dust Mite Allergy - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

House Dust Mite Allergy - Products under Development by Companies

House Dust Mite Allergy - Companies Involved in Therapeutics Development

ALK-Abello A/S

Anergis SA

Biomay AG

Circassia Pharmaceuticals Plc

DBV Technologies S.A.

HAL Allergy BV

Stallergenes S.A.

House Dust Mite Allergy - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AllerDM - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for House Dust Mite Allergy - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BM-35 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MK-8237 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PL-103 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

STG-320 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy - Drug Profile

Product Description

Mechanism of Action

R&D Progress

House Dust Mite Allergy - Recent Pipeline Updates

House Dust Mite Allergy - Dormant Projects

House Dust Mite Allergy - Discontinued Products

House Dust Mite Allergy - Product Development Milestones

Featured News & Press Releases

Jun 09, 2015: ALK’s partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal

Jun 04, 2015: ALK announces top-line results from its partner MSD's North American Phase III trial of house dust mite SLIT-tablet

Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet

Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet

Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development

Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet

Sep 12, 2013: Circassia's house dust mite allergy treatment achieves long-term symptom reduction

Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma

Jun 19, 2013: Anergis Files Provisional US Patent On AllerDM Dust Mite Allergy Treatment

Jun 19, 2013: ALK-Abello's New Allergy Immunotherapy Tablet Meets Primary Endpoint In Pivotal Phase III Trial In Patients With House Dust Mite Allergy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for House Dust Mite Allergy, H2 2015

Number of Products under Development for House Dust Mite Allergy - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H2 2015

House Dust Mite Allergy - Pipeline by Anergis SA, H2 2015

House Dust Mite Allergy - Pipeline by Biomay AG, H2 2015

House Dust Mite Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2015

House Dust Mite Allergy - Pipeline by DBV Technologies S.A., H2 2015

House Dust Mite Allergy - Pipeline by HAL Allergy BV, H2 2015

House Dust Mite Allergy - Pipeline by Stallergenes S.A., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

House Dust Mite Allergy Therapeutics - Recent Pipeline Updates, H2 2015

House Dust Mite Allergy - Dormant Projects, H2 2015

House Dust Mite Allergy - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for House Dust Mite Allergy, H2 2015

Number of Products under Development for House Dust Mite Allergy - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

ALK-Abello A/S
Anergis SA
Biomay AG
Circassia Pharmaceuticals Plc
DBV Technologies S.A.
HAL Allergy BV
Stallergenes S.A.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Cache

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare